profit from every $100 of sales.
$0$100
Theriva Biologics
$0.16+4.35% today
-41.7% in 1 year
1-year low $0.151-year high $0.41
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Theriva Biologics sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$23.7 million of profit last year.
SalesProfit
Theriva Biologics vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Theriva Biologics | No profit yet | ||
 Vertex Pharmaceuticals | 35.1× · Expensive | ||
 Moderna | No profit yet | ||
 Regeneron Pharmaceuticals | 21.0× · Fair price | ||
 CSL | 22.0× · Fair price |
AI analysis
An AI analyst reads Theriva Biologics's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -22 | -21 | -19 | -24 | |
| -21 | -21 | -19 | -24 | |
| -20 | -18 | -26 | -24 | |
| -32.75 | -28.48 | -19.03 | -2.08 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 72 | 55 | 35 | 38 |
| Cash | 42 | 23 | 12 | 13 |
| Total debt | 2 | 2 | 2 | 3 |
| Total liabilities | 17 | 16 | 16 | 23 |
| 55 | 40 | 19 | 15 | |
| 1 | 1 | 1 | 12 | |
| -30.3% | -40.5% | -74.4% | -105.5% | |
| -36.1% | -46.2% | -134.5% | -154.3% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -19 | -19 | -17 | -17 | |
| 0 | 0 | 0 | 0 | |
| -19 | -19 | -17 | -17 | |
| Dividends paid | – | – | – | – |
| 0 | 0 | – | – | |
| 0 | 1 | 1 | 1 |
Valuation
- –
- –
- –
- 0.9×
- –
- –
- 0.0×
- -236.0%
- -356.8%
- 0.0%
Profitability
- 92.0%
- -7,245.0%
- -7,153.0%
- -7,183.3%
- -76.2%
- -72.9%
- -178.3%
- -56.1%
- -77.7%
- 1,997.0%
Growth
- –
- –
- +1.4%
- –
- −0.1%
Financial health
- 0.6×
- 0.13
- 5.4%
- –
- 1.63
- 1.63
- 0.01
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 2%of 968
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 5, 2026 | -0.05 | -0.05 | +0.0% |
| Mar 12, 2026 | 1.85 | -0.44 | +525.3% |
| Nov 12, 2025 | -0.45 | -0.38 | −18.4% |
| Aug 11, 2025 | -1.93 | -0.38 | −407.9% |
| May 14, 2025 | -1.55 | -4.19 | +63.0% |
| Mar 6, 2025 | -3.30 | -6.36 | +48.1% |
| Nov 12, 2024 | -6.81 | -6.25 | −9.0% |
| Aug 13, 2024 | -5.50 | -4.75 | −15.8% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/6Passes 1 of 6. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
55No pass
Benjamin Graham
62Pass
Philip Fisher
59No pass
Peter Lynch
–Not enough data
Joel Greenblatt
52No pass
Charlie Munger
54No pass
Terry Smith
48No pass
Questions about Theriva Biologics
Is Theriva Biologics a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 6 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Theriva Biologics AI analysis
What does Theriva Biologics do?
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. It is in Biotechnology.
Does Theriva Biologics pay a dividend?
No. Theriva Biologics does not pay a dividend at the moment.
Is Theriva Biologics stock halal?
No. Theriva Biologics does not pass our halal screen: its debt is 37% of its market value, at or above the 33% limit. How we check
How has Theriva Biologics stock done over the past year?
Down 41.7% over the past twelve months, to $0.16. It traded between $0.15 and $0.41 and is 60.8% below its high.
Who are Theriva Biologics's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals and CSL. The peers table on this page compares their profit, growth and price with Theriva Biologics's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.